# Open Label Extension of TUDCA-ALS Study

> **NCT05753852** · PHASE3 · UNKNOWN · sponsor: **Humanitas Mirasole SpA** · enrollment: 184 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Tauroursodeoxycholic Acid

## Key facts

- **NCT ID:** NCT05753852
- **Lead sponsor:** Humanitas Mirasole SpA
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-25
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2023-03-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05753852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05753852, "Open Label Extension of TUDCA-ALS Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05753852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*